enVVeno MEDICAL

Setting New Standards for Venous Care

October 2021
Investor Presentation

Nasdaq: NVNO
enVVeno.com

Legal Disclaimers

This presentation and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results (including, without limitation, with respect to our name change, our progress with the VenoValve® and the expected timeline related to the SAAVE U.S. pivotal trial, including the timing of beginning patient enrollment, the VenoValve®'s ability to fill the unmet medical needs of CVI sufferers and our development of a second device for the treatment of venous disease) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

Investment Highlights

VenoValve

Lead product candidate, VenoValue® being evaluated for the treatment of lower limb deep venous Chronic Venous Insufficiency (CVI)

Demonstrated efficacy and safety in first-in-human trial

Ongoing SAVVE pivotal trial with data expected Q4 2022

Sufficient capital to fund operations through pivotal data readout

VenoValve

Potential to redefine the standard of care in lower limb Chronic Venous Insufficiency (CVI)

Breakthrough Device Designation

Significant opportunity with
~2.4 million potential patients in the U.S.




VenoValve
View Video

Chronic Venous Insufficiency (CVI)

Occurs as a result of increased venous pressure (venous hypertension) within the veins of the leg, most often caused by failure of valves within the veins



Leads to:

- Reflux – blood flows in the wrong direction
- Blood pooling in the lower leg
- Venous hypertension
- Pain
- Edema
- Ulceration

CVI Patients Need an Effective Treatment

~2.4M
People in the U.S.[1]

~$30k
Spent on wound care per patient per year[2]

20-40%
1-Year ulcer recurrence[1]

~$30B
Direct medical costs[2]

~40%
More workdays missed[3]

1. Yost, Mary, The Sage Group, Chronic Venous Disease, Epidemiology, Costs, and Consequences, 2016
2. Sachdev, Ulka, et. al. Suppressed Networks of Inflammatory Mediators Characterize Chronic Venous Insufficiency, Journal of Vascular Surgery: Venous and Lymphatic Disorders, May 2018
3. Rice, J. Bradford, Burden of Venous Leg Ulcers in the United States, Journal of Medical Economics, Volume 17, 2014

Deep Venous CVI: Current Standard of Care

Compression Garments

Leg Elevation

CVI: Trial Endpoints

Safety

Number device related adverse events

Reflux



Backwards flow of blood measured via a duplex scan

rVCSS
(Venous Clinical Severity Score)



Progressive ranking of disease manifestations and severity

Pain VAS
(Visual Analogue Score)

Numerical score of the severity of the perception of pain

Positive Results from First-In-Human Trial[1]

Demonstrated Meaningful Improvements Across All Primary and Secondary Endpoints at Two Years



1. No device related adverse events. Safety issues in first year included 1 seroma (which was aspirated), 3 minor wound infections, 1 over anticoagulation and 1 occlusion due to patient non-compliance. No reported safety event between years 1 and 2.
2. One year results for 11 patients compared to Pre-VenoValve® implantation. Two year results for 8 patients compared to Pre-VenoValve® implantation

VenoValve Venous Ulcer Healing

Results from First-in-Human Trial



BEFORE



AFTER

BEFORE



AFTER



BEFORE



AFTER



SAVE Upcoming Pivotal Trial

Full Enrollment Expected 1H 2022

Prospective, Non-Blinded, Single Arm, Multi-Center Study

75 Patients



Up to **20 Sites** across the U.S.

Primary Safety Endpoint	30 Days	Primary Efficacy Endpoint	6 Months

Expect to Have Topline Safety and Efficacy Data Q4 2022

Pivotal Trial Compared to First-In-Human



VenoValve

Commercial Strategy

Stakeholder Appeal

Patients

- Potential to cure debilitating disease
- No effective alternatives

Doctors

- No existing treatment
- Short learning curve
- Incremental revenue

Hospital (VAC)



- No capital investment
- Profitable procedure
- Eliminate wound care

Payers



- $30,000-year wound care
- High recurrence
- Society and KOL support

Focused Commercial Rollout Strategy



Commercial Manufacturing

14,000 square foot facility
in Irvine, CA

Capacity to support at least first 5 years of commercialization

Limited capital investment in plant and equipment for commercialization

Corporate Overview

Potential for Significant Value Creation



Financial Overview

Sufficient Capital to Fund Operations Through Topline Data of SAVVE Pivotal Trial

52-week range

$4.99 (low) | $9.82[1] (current) | $17.68 (high)

Cash Balance
$43M
as of June 30, 2021

$20M
Does not include net proceeds from Perceptive Advisors
September 7, 2021

$0	~$93M	~9.5M	~16.1M
Debt	Market Cap[1]	Shares Outstanding	Fully Diluted

1: As of October 5, 2021

Management Team

ROBERT BERMAN

Chief Executive Officer, Director

- Former CEO – Anixa Biosciences (Nasdaq:ANIX)
- Former COO Acacia Research Corporation (Nasdaq:ACTG)
- B.S. Wharton, Univ. of Pennsylvania, JD Northwestern Law

DR. MARC GLICKMAN

Senior VP and Chief Medical Officer

- Board Certified Vascular Surgeon
- Director of Vascular Services – Sentara Health Care
- Past President – Vascular Society of America

DR. HAMED ALAVI

VP Research and Development

- Edwards Lifesciences, Medtronic
- PhD Biomedical Engineering – U.C. Irvine
- M.S. Biomedical Engineering, B.S. Mechanical Engineering

CRAIG GLYNN

Chief Financial Officer

- Over 30 years financial experience
- M.S. and B.S. Accounting – California State University Northridge
- Member – American Institute of CPAs

Collective Industry Experience

Medtronic COVIDIEN Baxter Edwards LIFESCIENCES SENTARA®

Board of Directors

DR. FRANCIS DUHAY

Director

- Former Chief Medical Officer – Edwards Lifesciences
- Expert in surgical and transcatheter heart valves
- General manager Acendra business unit

DR. SANJAY SHRIVASTAVA

Director

- Business Development – Johnson and Johnson
- 18 years – VP Marketing and Strategy, R&D
- BTG, Medtronic, Abbott Vascular, Edwards Lifesciences

MATTHEW JENUSAITIS

Director

- Chief of Staff and Chief of Innovation and Transformation – UC San Diego Health System
- Former President Boston Scientific – Peripheral Division
- Four successful vascular company exits

BOB GRAY

Director*

- Former Chief Financial Officer – Highmark, Inc.
- Health insurer with over 20 years subscribers
- Rate setting and reimbursement negotiations

*Chairman, Audit Committee

Collective Industry Experience

Medtronic

Edwards LIFESCIENCES

Boston Scientific

BTG

Johnson & Johnson

HIGHMARK

Abbott Vascular

enVVeno MEDICAL

Upcoming Milestones



Investment Summary

Potential for Huge Upside with Managed/Limited Risk
We Believe Upside Far Outweighs the Risk

Clinical	Capital	Execution
Demonstrated efficacy and safety in first-in-human trial	Sufficient capital to fund operations through topline data of SAVVE pivotal trial	World-class team of executives and advisors driving execution

Setting New Standards for Venous Care

Appendix

Cap Table

Common Stock Outstanding		**9,466,240**
Warrants		
Perceptive Pre-Funded Warrants*		**1,759,035**
Other Warrants		
Exercise Price:		
$7	2,957,142	
$7 - $10	906,917	
$10 - $50	536,812	
> $50	153,600	
Total Warrants		**4,554,471**
Equity Incentive Plan		**386,096**
Total Common Stock, Warrants and Options Outstanding		**16,165,842**
Total Authorized Shares		250,000,000
Preferred		10,000,000